Industry Insights AI: 10/10/25
In this round of insights, we highlight discussions from the Patient-Centered Oncology Care (PCOC) conference, perspectives on genomics in cancer care and new survey findings on AI in health care claims management
AI and collaboration at PCOC 2025
On 25–26 September, oncology experts gathered in Nashville for this year’s PCOC conference under the theme ‘Finding Our Rhythm: Embracing Change in Oncology Care’. Panel discussions explored the growing influence of AI and the need for stronger partnerships among providers, payers and manufacturers. Scott Soefje, director of pharmacy cancer care at Mayo Clinic, noted that AI is envisioned at all levels of oncology care, from integrating genomic and precision medicine data into decision-making to converting data into actions.
AI and genomic testing in precision oncology
During PCOC, Vivek Subbiah, chief of early-phase drug development at Sarah Cannon Research Institute, stressed that cancer is fundamentally a genetic disease and that somatic and germ-line testing should be part of every diagnosis. Advances in genomically targeted therapies, immunotherapies and antibody–drug conjugates (ADCs) make testing increasingly vital. However, access to testing remains a challenge as many patients are only tested in the late stages of disease.
Subbiah emphasised that AI can help integrate large volumes of data into actionable insights. ‘Given the volume of data and information we have from genomics, proteomics, and transcriptomics, it’s humanly impossible to put all these pieces of information together. I think that’s why we depend on AI, that’s defined by either machine learning or large language model systems’, said Subbiah.
AI can help reduce healthcare denial claims
Data from Experian Health’s 2025 State of Claims survey show healthcare claim denials are on the rise. Causes include missing data, prior authorisation issues and staffing shortages. Although 67% of the surveyed providers believe AI can improve the claims process, only 14% have adopted AI tools. Those using AI report reduced denials and improved resubmissions. However, barriers such as compliance, training and payer-specific rules remain challenges. Denial reduction is a top priority for 82% of providers, thus making AI-enabled tools a strategic investment.
Want to get in touch? Contact us at https://elion.nz/get-in-touch/
